Compare LFVN & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | NSRX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 53.5M |
| IPO Year | 1996 | N/A |
| Metric | LFVN | NSRX |
|---|---|---|
| Price | $4.40 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 97.6K | ★ 160.9K |
| Earning Date | 05-05-2026 | 03-20-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | ★ 226.09 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $203,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.63 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $2.14 |
| 52 Week High | $16.14 | $9.99 |
| Indicator | LFVN | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 25.92 |
| Support Level | $4.32 | N/A |
| Resistance Level | $5.37 | $5.20 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 23.70 | 0.00 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.